Amygdala Reactivity, Antidepressant Discontinuation, and Relapse

Area of Science:

• Neuroscience
• Psychiatry
• Neuroimaging

Background:

• Antidepressant discontinuation significantly elevates the risk of depression relapse.
• The neurobiological underpinnings of this relapse risk remain largely unknown.
• Amygdala reactivity to negative stimuli is a key indicator of affective processing in depression, modulated by antidepressant treatment.

Purpose of the Study:

• To determine if amygdala reactivity to negative facial emotions changes following antidepressant discontinuation.
• To investigate the association between altered amygdala reactivity and the risk of subsequent depression relapse.

Main Methods:

• Longitudinal observational study (Antidepressiva Absetzstudie [AIDA]) involving patients with remitted major depressive disorder (MDD).
• Two task-based functional magnetic resonance imaging (fMRI) scans measuring amygdala reactivity.
• Randomized discontinuation of antidepressants before or after the second fMRI scan, with 6-month relapse monitoring.

Main Results:

• Initial amygdala reactivity did not differ between patients with remitted MDD and healthy controls.
• An increase in amygdala reactivity post-discontinuation was significantly associated with depression relapse (P=.04).
• Changes in amygdala reactivity predicted shorter time to relapse and were predictive of relapse (balanced accuracy, 67%).

Conclusions:

• Increased amygdala reactivity following antidepressant discontinuation is linked to a higher risk of depression relapse.
• This change in amygdala reactivity may serve as a functional neuroimaging marker.
• Findings could inform clinical strategies for managing antidepressant discontinuation.